scholarly journals SPECTRUM

2016 ◽  
Vol 11 (2) ◽  
pp. 284-289 ◽  
Author(s):  
Bernhard Gehr ◽  
Martin Holder ◽  
Bernhard Kulzer ◽  
Karin Lange ◽  
Andreas Liebl ◽  
...  

Background: Optimal usage of continuous glucose monitoring (CGM) requires adequate training of the users. Providing patients with a CGM system without such a training usually doesn’t lead to the intended improvement in metabolic control. Methods: In Germany we developed a structured training program (“SPECTRUM”) to ensure a high quality standard for the use of CGM systems. Results: This program is suitably for patients of all age groups and is applicable to all CGM systems and all forms of insulin therapy. A curriculum was also developed so that training centers with less experience with CGM could become capable of offering comprehensive CGM training. Conclusions: We believe that usage of such a program can be an important step forward in achieving more widespread acceptance and use of CGM systems. Translations in other languages and evaluation with a controlled clinical trial are planned.

2021 ◽  
Vol 3 (1) ◽  
pp. 179-180
Author(s):  

The peer review process represents the driving force of journal development, with reviewers acting as the gatekeepers who ensure that Clocks & Sleep maintains its high-quality standard of published papers [...]


Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Ying Zhao ◽  
Yuan-Yuan Yang ◽  
Bao-Lin Yang ◽  
Ya-Wei Du ◽  
Da-Wei Ren ◽  
...  

Abstract Background Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease and a leading cause of death worldwide. The clinical utility of commonly used lipid-lowering drugs such as statins and fibrates is sometimes limited by the occurrence of various adverse reactions. Recently, berberine (BBR) has received increasing attention as a safer and more cost-effective option to manage dyslipidemia. Thus, a high-quality randomized controlled trial to evaluate the efficacy and safety of BBR in the treatment of dyslipidemia is deemed necessary. Methods/design This is a randomized, double-blind, and placebo-controlled clinical trial. A total of 118 patients with dyslipidemia will be enrolled in this study and randomized into two groups at a ratio of 1:1. BBR or placebo will be taken orally for 12 weeks. The primary outcome is the percentage of low-density lipoprotein cholesterol reduction at week 12. Other outcome measures include changes in other lipid profiles, high sensitivity C-reactive protein, blood pressure, body weight, Bristol Stool Chart, traditional Chinese medicine symptom form, adipokine profiles, and metagenomics of intestinal microbiota. Safety assessment includes general physical examination, blood and urine routine test, liver and kidney function test, and adverse events. Discussion This trial may provide high-quality evidence on the efficacy and safety of BBR for dyslipidemia. Importantly, the findings of this trial will help to identify patient and disease characteristics that may predict favorable outcomes of treatment with BBR and optimize its indication for clinical use. Trial registration Chinese Clinical Trial Registry ChiCTR1900021361. Registered on 17 February 2019.


2012 ◽  
Vol 2 ◽  
pp. 60-68
Author(s):  
Riaz Husssin Shaikh ◽  

Sanitation and Cleanliness plays a very important role in the manufacturing of efficacious, safe pharmaceuticals of high quality standard. A little carelessness or negligence in the follow up of the procedure can have adverse end result on the final product.


2017 ◽  
Vol 5 (14) ◽  
Author(s):  
Erin P. Price ◽  
Melissa Laird Smith ◽  
Ellen E. Paxinos ◽  
Luke J. Tallon ◽  
Lisa Sadzewicz ◽  
...  

ABSTRACT We report here paired isogenic Burkholderia pseudomallei genomes obtained from three patients receiving intravenous meropenem for melioidosis treatment, with post-meropenem isolates developing decreased susceptibility. Two genomes were finished, and four were drafted to improved high-quality standard. These genomes will be used to identify meropenem resistance mechanisms in B. pseudomallei.


2020 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Houman Hashemian ◽  
Hamid Alizadeh ◽  
Ehsan Kazemnejad Leyli

Background: Pneumonia remains one of the leading causes of childhood mortality and morbidity in developing countries. Studies showed that zinc supplementation can prevent pneumonia, but its therapeutic effectiveness has not been determined definitively. Objectives: This study evaluated the effect of zinc supplementation as adjuvant treatment on children with severe pneumonia admitted to 17th Shahrivar Training Hospital in Rasht, Iran. Methods: In this double-blind placebo-controlled clinical trial, 120 children aged two to 60 months hospitalized for pneumonia were randomly divided into 2 groups of size 60 each. The first group received zinc sulfate (20 mg daily for children twelve months of age or older and 10 mg daily for children younger than 12 months), and the second group received a placebo for seven days. All patients received standard antibiotic treatment for pneumonia. The children were daily evaluated, and recovery time for fever and tachypnea (as primary outcomes) and duration of hospitalization and mortality rate (as secondary outcomes) were compared between the two groups. Results: The mean age of patients was 14.1 months ± 13.9. The youngest and oldest patients were aged 2 and 60 months, respectively. No significant difference in age and sex distribution was found between the two groups. The zinc receiving group experienced a considerably shorter time of fever (2.1 days vs. 2.84 days, P < 0.05) and tachypnea (1.75 days versus 2.1 days, P = 0.011). There was no significant difference in the duration of admission between the two groups (P = 0.728), and no cases of death occurred in either group. Conclusions: This study showed that adjuvant treatment with zinc in children aged 2 to 60 months with severe pneumonia accelerates recovery from pneumonia. Further studies are needed to investigate the effects of administering zinc as adjunctive therapy for pneumonia in other age groups.


2012 ◽  
Vol 02 (04) ◽  
pp. 117-124
Author(s):  
María Elena de la Uz Herrera ◽  
Arturo Hernández Yero ◽  
Reinaldo González Iglesias ◽  
Urbicio Reinoso Hernández ◽  
Alfredo Novales Amado ◽  
...  

Technologies ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 8
Author(s):  
Ioanna Dratsiou ◽  
Annita Varella ◽  
Evangelia Romanopoulou ◽  
Oscar Villacañas ◽  
Sara Cooper ◽  
...  

As people age, they are more likely to develop multiple chronic diseases and experience a decline in some of their physical and cognitive functions, leading to the decrease in their ability to live independently. Innovative technology-based interventions tailored to older adults’ functional levels and focused on healthy lifestyles are considered imperative. This work proposed a framework of active and healthy ageing through the integration of a broad spectrum of digital solutions into an open Pan-European technological platform in the context of the SHAPES project, an EU-funded innovation action. In conclusion, the SHAPES project can potentially engage older adults in a holistic technological ecosystem and, therefore, facilitate the maintenance of a high-quality standard of life.


2021 ◽  
Vol 4 (27) ◽  
pp. 93-99
Author(s):  
A.L. Zelezinskii ◽  
◽  
O.V. Arhipova ◽  
D.V. Hodos ◽  
A.V. Fedorova ◽  
...  

Regional economic policy as part of the overall socio-economic policy of the country is important for the development not only of the regions, but also for the sustainable and stable development of the country, ensuring a high-quality standard of living of the popu-lation. The well-being of the country as a whole and its population in particular de-pends on the economic development of each district.


Sign in / Sign up

Export Citation Format

Share Document